Mitiperstat

DB18963InvestigationalSmall molecule

Mitiperstat is under investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.).

Formula / weight: C₁₅H₁₅ClN₄OS · 334.82 g/mol (avg)
Also known as: 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one · 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-
Code names: AZD-4831

Resolves to

Compound

UNIIS6GYK3X4QQCAS1933460-19-5ChEMBLCHEMBL5095218

Structure

InChIKeyBHKKSKOHRFHHIN-MRVPVSSYSA-NSMILESC[C@@H](N)C1=CC(Cl)=CC=C1CN1C2=C(NC=C2)C(=O)NC1=S

Targets

P05164MPO

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Mitiperstat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account